NBT828 is an innovative ADC drug for breast cancer, which was developed based on NewBio Therapeutics’ proprietary site-specific linker (BiM) technology. The ADC product is highly homogeneous, with average drug/antibody ratio (DAR) around 4 and DAR4 components around 85%. This project is in clinical phase I stage.